Cochrane · systematic review · CD011224
Leukotriene receptor antagonists for eczema
Ferguson, L, Futamura, M, Vakirlis, E, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
6
No studies
8
Included studies
NR
No studies 8 · 57.1%Ungraded 0 · 0%Very low 1 · 7.1%Low 5 · 35.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Montelukast versus placebo for eczema
Population: eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change (improvement) in disease severity (4 to 8 weeks) SMD (modified EASI score and SASSAD) Montelukast vs placebo | no estimate extracted | 3 studies · 131 participants | Low Downgraded: imprecision, indirectness |
Effect of long‐term control (> 3 months) Montelukast vs placebo | no estimate extracted | NR | No studies |
Adverse effects (4 to 8 weeks) Montelukast vs placebo | no estimate extracted | 3 studies · 131 participants | Low Downgraded: imprecision, indirectness |
Requirement for corticosteroid (steroid‐sparingeffect) Montelukast vs placebo | no estimate extracted | 1 study · 58 participants | Low Downgraded: imprecision, indirectness |
Reduction of pruritus (score range 0 to 10; higher score means better improvement) Montelukast vs placebo | no estimate extracted | 1 study · 58 participants | Low Downgraded: imprecision, indirectness |
Improvement in quality of life Montelukast vs placebo | no estimate extracted | NR | No studies |
Need for emollient use Montelukast vs placebo | no estimate extracted | NR | No studies |
Montelukast versus conventional treatment for eczema
Population: eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change (improvement) in disease severity (4 weeks) SCORAD score Montelukast vs conventional treatment | no estimate extracted | 1 study · 31 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Effect of long‐term control (> 3 months) Montelukast vs conventional treatment | no estimate extracted | NR | No studies |
Adverse effects (4 to 6 weeks) Montelukast vs conventional treatment | no estimate extracted | 2 studies · 63 participants | Low Downgraded: imprecision, indirectness |
Requirement for corticosteroid (steroid‐sparingeffect) Montelukast vs conventional treatment | no estimate extracted | NR | No studies |
Reduction of pruritus Montelukast vs conventional treatment | no estimate extracted | NR | No studies |
Improvement in quality of life Montelukast vs conventional treatment | no estimate extracted | NR | No studies |
Need for emollient use Montelukast vs conventional treatment | no estimate extracted | NR | No studies |